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Background: Malaria continues to be amongst the most frequent infectious diseases imported to Europe.
Whilst European treatment guidelines are based on data from studies carried out in endemic areas, there is a
paucity of original prospective treatment data. The objective was to summarize data on treatments to
harmonize and optimize treatment for uncomplicated malaria in Europe.
Methods: A prospective observational multicentre study was conducted, assessing tolerance and efficacy of
treatment regimens for imported uncomplicated falciparum malaria in adults amongst European centres of tropical
and travel medicine.
Results: Between December 2003 and 2009, 504 patients were included in 16 centres from five European countries.
Eighteen treatment regimens were reported, the top three being atovaquone-proguanil, mefloquine, and
artemether-lumefantrine. Treatments significantly differed with respect to the occurrence of treatment changes
(p = 0.005) and adverse events (p = 0.001), parasite and fever clearance times (p< 0.001), and hospitalization
rates (p = 0.0066) and durations (p = 0.001). Four recrudescences and two progressions to severe disease were
observed. Compared to other regimens, quinine alone was associated with more frequent switches to second line
treatment, more adverse events and longer inpatient stays. Parasite and fever clearance times were shortest with
artemether-mefloquine combination treatment. Vomiting was the most frequent cause of treatment change,
occurring in 5.5% of all patients but 9% of the atovaquone-proguanil group.
Conclusions: This study highlights the heterogeneity of standards of care within Europe. A consensus discussion
at European level is desirable to foster a standardized management of imported falciparum malaria.
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With approximately 11,000 reported cases annually,
malaria remains the most important tropical disease
imported into Europe both in clinical terms and in abso-
lute figures [1,2]. The majority of cases are caused by
Plasmodium falciparum, which can lead to complicated
disease and death if not treated early. Even in uncompli-
cated cases, which constitute the majority of cases [3],
treatment costs (evaluated in 2005 at €17,416,955/year
for 6,321 cases in France) and resulting costs continue
to pose a significant strain on the European health
systems, which cannot be ignored [4].
Assuming that efficacy and tolerance are similar in
imported malaria, the recommended therapy is based on
data predominantly derived from therapeutic studies
performed in endemic areas [5-14]. Nevertheless, for
epidemiological and biological reasons results are not
always applicable in the particular field of imported
malaria. For example, differences in age and (lack of )
background immunity may influence the duration and
characteristics (fever and parasite clearance times,
adverse events encountered) of the treatment period.
The combination atovaquone-proguanil, largely used
in non-endemic countries, has neither been tested
extensively in endemic areas nor in non-endemic areas
since conducting large studies appears not to be feasible
[15-18]. Compared to atovaquone-proguanil and the ‘clas-
sical’ drugs, such as quinine, mefloquine or halofantrine,
published clinical experience with artemether-lumefantrine
for the treatment of uncomplicated falciparum malaria is
scarce. Very few studies with limited number of subjects
(and only one comparative) are available and, in addition,
even if registered throughout Europe in 1999, the drug is
still not easily available [19,20]. For example, artemether-
lumefantrine was marketed in Germany in 2000, but in
France only in 2007, and it is still unavailable in Italy. As
a result, use of anti-malarials in non-endemic countries
remains, to a certain extent, empirical as comparative
studies between competing regimens are lacking.
The overall aim of this multicentre observational study
is to summarize data on treatment regimens in Europe,
in order to harmonize treatment modalities for uncom-
plicated falciparum malaria, and to optimize drug treat-
ment strategies amongst European centres of tropical
and travel medicine.
Methods
Study design and population
The centres contributing to this prospective observa-
tional multicentre study were self-selected members of
the then clinical surveillance networks TropNetEurop
and SIMPID. Patients with uncomplicated falciparum
malaria were recruited at the participating centres
between December 2003 and December 2009. Criteriafor study inclusion were parasitologically confirmed un-
complicated falciparum malaria with or without chemo-
prophylaxis, no previous malaria therapy for the same
episode of illness, and informed consent. Exclusion
criteria were age less than 18 years, complicated/severe
falciparum malaria on inclusion, or refusal of consent.
Pregnancy was not an exclusion criterion due to the
observational design of the study. Mixed infections were
excluded for comparability reasons.
The primary objective of the study was to describe the
profile of anti-malarial regimens used in Europe with a
focus on safety and tolerability. Investigated indicators for
safety and tolerability were rate and reasons of treatment
change, and type, rate and severity of adverse events.
Secondary endpoints were clinical and parasitological
cure on days 7 and 28, and duration of hospitalization.
Clinical cure was determined as fever clearance time
in hours and parasitological cure as parasite clearance
time in hours on the grounds of expert microscopy of at
least 100 visual fields of a Giemsa-stained thick film.
Allocation to the particular therapeutic regimen was
done by the individual participating centres based on
country- or centre-specific recommendations, practice
pattern, and individual patient’s situation in terms of
past exposure, prophylaxis intake, co-morbidity, etc.
Randomization was not performed. Doses were given on
the basis of manufacturers’ recommendations.
Data were collected anonymously at each participating
centre with an electronic entry and reporting tool linked
to the regular network surveillance software. In order to
assess a standardized and complete minimal dataset
from each centre, the tool was equipped with mandatory
entry fields, predefined answer categories and data for-
mats and built-in plausibility checks. Treatment outcome
was assessed in a standardized follow-up procedure. If
feasible, post-discharge control examinations were per-
formed on day 28. If not feasible, a telephone survey was
to be carried out on day 28 to detect possible treatment
failures and possible late-onset adverse events of drug
therapy. The adverse events reporting section of the
study software was structured in order to be able to dif-
ferentiate between signs attributable to the disease itself
and to the drug, and to assess their severity. Completed
cases were sent electronically to the TropNetEurop/
SIMPID coordination centre using the export function of
the study software.
Data analysis
Statistical analysis was performed using SAS software
(release 9.1 by SAS Institute Inc., Cary, NC, USA). For
each study endpoint the heterogeneity of treatment regi-
mens was first assessed with an overall test. In the case
of a significant result, each regimen was tested against
all others using a Bonferroni-Holm adjustment for
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using chi-square or Fisher’s exact tests. If asymptotic
chi-square tests yielded unreliable results and exact tests
were unfeasible due to limited computational resources,
Monte Carlo estimates for the exact test based on one
million replications were performed. Continuous data
were analyzed using a Wilcoxon or Kruskal-Wallis test.
For stratum-adjusted analysis of categorical and continu-
ous data, The Cochran-Mantel-Haenszel test for general
association and Friedman’s test were applied, respectively.Ethical considerations
An umbrella ethical approval was granted by the site
hosting the principal investigator (MPG) at the time
point of study initiation. Few centres required, and were
granted, additional site-specific approval.
Results
Five hundred and four malaria patients were included in
16 different centres from five European countries. The
contribution of patients by the various centres was het-
erogeneous, ranging from one to 141. The three main
countries providing patients were, by order of number of
patients, France, Italy and Germany, respectively.
Patient characteristics are summarized in Additional
file 1, stratified by regimen. The majority of patients
were migrants living in Europe and visiting friends and
relatives (VFR) (69%). Most were infected in West Africa
(59.5%). Only 2% contracted Plasmodium spp. in
endemic areas other than sub-Saharan Africa. Median
age was 38 years, with a male:female sex ratio of 1.6.
Before travelling, a minority of patients sought medical
advice (27%) and/or took an at least partially effective
chemoprophylaxis (26%). Median travel duration was
one month, with a few patients acquiring malaria with
exposure as short as four days. The median delay
between onset of symptoms and diagnosis was three
days. At time of diagnosis, median temperature was
39.0 °C and parasitaemia varied between very low dens-
ity to hyperparasitaemia (maximum at 854,000/μL).
A total of 18 different regimens were observed: eight
comprising 98% of the prescribed treatments, the 10 other
regimens being based either on artemisinine derivatives
alone or associated to various anti-malarials in six cases
or on quinine associated mainly to pyrimethamine and
sulphadoxine at different dosages. Atovaquone-proguanil,
artemether-lumefantrine and quinine were used in four
countries. Mefloquine was reported only from German
and Italian centres, the association β-artemether +
mefloquine only in one centre in Italy, intravenous quin-
ine followed by atovaquone-proguanil mainly in one
centre in France (in vomiting patients), the combination
quinine-clindamycin mainly in another French centreand the combination quinine-tetracycline mainly in
Belgium. In 90% of cases, patients received only
one regimen.
Overall, most patients were hospitalized (81.2%;
n = 409), but differences in the rate of hospitalization
between both the different treatment groups (p = 0.0056)
and the different countries participating in the study
(p< 0.0001) were observed. The rate of hospitalization
between countries was as follows: 100% in Belgium (one
centre), 98.7% in Germany (eight centres), 87.1% in Italy
(four centres), 85.7% in the UK (one centre) and 71.4%
in France (three centres).
Globally, the rate of adverse events (at least one event
reported) was 16% (n = 82) with differences between
treatment groups (p <0.001) (Table 1). Compared to
other drugs, quinine alone had a higher rate of adverse
events (p = 0.0273). When comparing each drug to each
other, quinine administration alone or in association
with clindamycin also led to a higher rate of adverse
events compared to artemether-lumefantrine (p = 0.0089
and 0.038, respectively). No severe clinical or biological
adverse events were reported. The top eight adverse
events (each concerning ≥5% of patients) were by
numeric decreasing order: vomiting, dizziness, nausea,
hearing impairment, headache, skin problems, sleep dis-
turbance and diarrhoea (Figure 1). Overall, 5.5% (n = 28)
of the patients experienced vomiting (isolated or in asso-
ciation with other adverse events) with differences
between treatment regimens (p = 0.0399). Vomiting was
observed with atovaquone-proguanil (n = 20; 71%), mef-
loquine alone (n = 7; 25%) and in one case with
artemether-mefloquine (4%). Hearing impairment and
dizziness were associated with quinine. Skin rashes (six
cases) were observed with atovaquone-proguanil, meflo-
quine, quinine alone, quinine + atovaquone-proguanil
or clindamycin. Dizziness was reported in 10 cases
(10%) of treatment with only mefloquine.
Overall, treatment change was necessary in 53 (10%)
of the 504 cases; with reasons for change differing
between treatment regimens (p = 0.0053). When com-
paring each regimen to all others, quinine monotherapy
was more often associated to change regimen (p 0.0004).
Frequency of treatment changes varied from 0 with
quinine-atovaquone-proguanil treatment to 24% with
quinine monotherapy. Globally, reasons for change were
vomiting in 30 cases (57%), adverse events other than
vomiting in 10 cases, progression to severe disease in
two cases, and various reasons in 11 cases. Vomiting
(attributed in 28 cases to adverse events and in two
patients treated with atovaquone-proguanil to malaria
itself ) led to a second-line treatment by intravenous
quinine in 24 cases (including nineteen on atovaquone/
proguanil and three on mefloquine). Atovaquone-
proguanil with a 9% proportion of treatment change due
Table 1 Tolerability and effectiveness of different treatment regimens in 504 malaria-patients in Europe
Total AQ+PG* MQ* AR+ LU* QUI* AR+MQ* QUI + CL* QUI + TC* QUI +AQPG* Other* Overall
test
p-Value
N=504 N=253 N=97 N=39 N=33 N=20 N=20 N=16 N=15 N=11
Treatment change, N (%) 0.0053a
• no change 451 (89.5) 223 (88.1) 92 (94.9) 37 (94.9) 25 (75.8) 19 (95.0) 17 (85.0) 13 (81.3) 15 (100.0) 10 (90.9)
• due to progress of severity} 2 (0.4) 2 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
• due to AE other than vomiting 10 (2.0) 2 (0.8) 0 (0.0) 1 (2.6) 5 (15.2) 1 (5.0) 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0)
• due to vomiting 30 (6.0) 22 (8.7) 5 (5.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (18.8) 0 (0.0) 0 (0.0)
• due to other reasons 11 (2.2) 4 (1.6) 0 (0.0) 1 (2.6) 3 (9.1) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 1 (9.1)
Pts. with any AE$, N (%) 82 (16.3) 34 (13.4) 22 (22.7) 1 (2.6) 12 (36.4) 2 (10.0) 7 (35.0) 2 (12.5) 2 (13.3) 0 (0.0) 0.0009 a
Parasite clearance time 72 72 54 72 48 36 48 48 72 48 <0.0001b
Hour median (min-max) (0-168) (0-168) (2-168) (24-168) (24-96) (12-96) (24-96) (24-108) (24-168) (0-96)
Fever clearance time, 48 48 24 48 24 16 48 72 48 36 <0.0001b
Hour median (min-max) (0-192) (0-192) (0-168) (0-72) (0-144) (0-80) (24-96) (24-96) (0-168) (4-60)
Duration of hospitalization# 4 4 4 4 6 3.5 5 5 3.5 4 0.0002 b
Day median (min-max) (1-18) (2-15) (1-18) (2-7) (1-13) (1-18) (3-7) (3-8) (3-7) (1-7)
Cure rate at day 28& 372/376 191/194 73/73 97.0 25/25 9/9 11/11 10/10 13/13 8/8 0.7371a
N cured/N followed-up (%) (98.9) (98.5) (100.0) (33) (100.0) (100.0) (100.0) (100.0) (100.0) (100.0)
a : Monte Carlo estimate for the exact chi-square test (1000000 samples); b : Kruskal-Wallis Test.
Figures in bold italics indicate Bonferroni-Holm adjusted p-values <0.05 in against all other comparison.
* : see additional file 1.
} : according to the WHO 2000 severity criterion.
$ : includes possible, mild adverse events.
# : N = 401 (95 non hospitalized patients and 8 with missing data).
& : complete case analysis (128 patients lost to follow-up not included in cure rate calculation; numbers of patients with follow-up data are given in the
denominators of the cure rate).
Bouchaud et al. Malaria Journal 2012, 11:212 Page 4 of 8
http://www.malariajournal.com/content/11/1/212to vomiting differed significantly from the overall aver-
age (p = 0.013).
Overall median parasite clearance time (PCT) was
72 hours, with significant differences between treatment
groups (p <0.001). When comparing one regimen to
the others, the shorter median PCT was observed in
patients treated by the association artemether-mefloquine
(36 hours; p <0.001) and the longer was with atovaquone-
proguanil (72 hours; p< 0.001). In pair wise comparisons
adjusted for multiple comparisons, PCT was shorter
with artemether-mefloquine compared to atovaquone-
proguanil (p< 0.001) and to mefloquine alone (p = 0.026)
but not compared to the combination artemether-
lumefantrine (p = 0.055).
Median fever clearance time (FCT) was 48 hours with
significant differences observed between treatment
groups (p <0.001). Compared to all other treatments,
median FCT was shorter in patients treated with
artemether-mefloquine (p = 0.008) or mefloquine alone
(p = 0.001) and was longer in patients treated with
quinine-tetracycline (p< 0.001). In multivariate analysis,pair-wise comparisons showed a shorter FCT between
artemether-lumefantrine and quinine-tetracycline (p=0.04),
mefloquine and atovaquone-proguanil (p = 0.03), meflo-
quine and quinine-tetracycline (p< 0.001), artemether-
mefloquine, and quinine-tetracycline (p = 0.005).
Duration of hospitalization differed between regimens
(p = 0.0002), even after adjusting for country-specific
effects (p <0.0001). Median duration was four days, with
25% hospitalized for more than five days, and 5% for
more than seven days (maximum of 18 days). Hospitaliza-
tion was longer with quinine alone (p =0.0229) or with
quinine-clindamycin (p=0.0156).
The overall cure rate was 74% in the intention-to-treat
analysis with a missing data rate due to loss to follow-up
of patients of 25%. Excluding those patients lost to follow-
up, the cure rate was 99% with four recrudescences occur-
ring in three cases treated with atovaquone-proguanil
and in one case treated with artemether-lumefantrine
(p> 0.05). Two cases of progression of the disease under
treatment were recorded (both with atovaquone-proguanil),
with no significant difference between regimens.
Figure 1 Distribution of adverse events in patients with adverse event.
Bouchaud et al. Malaria Journal 2012, 11:212 Page 5 of 8
http://www.malariajournal.com/content/11/1/212Discussion
This prospective observational study included 504 cases
of uncomplicated P. falciparum malaria managed in 16
different centres from five countries. This is to date
the largest study on imported malaria in terms of
numbers of patients. Patient profiles are similar to those
observed in the majority of studies on imported malaria
[1,2,15-26], except for the fact that there were very few
travellers to Asian destinations (e.g. to those areas were
mefloquine resistance is emerging). Most of the patients
were migrants living in Europe infected in West Africa.
Eighteen different treatment regimens were used.
Atovaquone-proguanil was predominantly used (half of
cases) followed by older drugs such as mefloquine (19%)
or quinine alone or in combination with clindamycin or
tetracyclines (14%) [25,27,28]. Artemether-lumefantrine
was used in only 8% of cases, but at the beginning of this
study, the drug was not easily available in Europe. Tak-
ing into account that some European countries do not
have national guidelines, the large variety of treatments
can be explained by the fact that all participating centres
are managed by tropical medicine experienced practi-
tioners who choose therapeutic regimens following dif-
ferent criteria, such as individual risk profiles, personal
clinical or research experiences, “local” behaviours, avail-
ability of drugs.
A vast majority of patients (81%) were hospitalized,
but differences were observed between centres with
hospitalization rates from 71% in France to nearly 100%
in Belgium or Germany. These differences can be
explained by the fact that usages and recommendations
differ considerably between countries (Table 2), and with
ambulatory treatment criteria remaining controversial
[21-24,29,30]. In the present period of restricted healthbudgets, and in addition to this high rate of hos-
pitalization, the median duration of hospitalization of
four days appears relatively long. The longer duration
observed with quinine alone or in combination with
clindamycin is probably due to the frequency of disab-
ling side effects (dizziness, hearing impairment, head-
aches) related to a seven-day regimen [31].
The cure rate of 99% (if patients lost to follow-up were
excluded from the analysis) is comparable to that one
observed in the literature on imported malaria based on
smaller series and equal or higher to studies performed
in endemic areas [5-18,32]. However, antimalarial drug
resistance (not only against P. falciparum, which is in
the focus of this paper) continues to emerge on a global
scale, already also including artemisinines, thus poten-
tially also jeopardizing the favourable primary treatment
outcomes as routinely observed in most travellers.
Four recrudescences were reported in three cases of
atovaquone-proguanil treatment and in one case of
artemether-lumefantrine treatment; both drugs necessi-
tating to be absorbed with a fatty meal due to the
lipophily of, respectively, atovaquone and lumefantrine
[33,34]. Details on these relapses are lacking for two
cases but for the other two occurring on atovaquone-
proguanil, the reason was probably poor absorption due
in one case to obesity (115 kg body weight) and conse-
quently under-dosing, and in the second case due to a
low atovaquone plasma level in a patient not having
taken food with the drug [35]. Consequently, physicians
have to stress that with both drugs, their patients should
take food.
The rate of patients lost to follow-up at day 28 was
high (25%), especially in certain treatment groups
where it reached 45% (quinine-clindamycin) or 55%
Table 2 Treatment recommendations and hospitalization
policies for imported, uncomplicated falciparum malaria
in selected European countries
First-line Hospitalization policy
treatment Recommendations (R)
or standard practice (SP)
Belgium Atovaquone-proguanil
Artemether-lumefantrine
SP : hospitalization
(ambulatory treatment
possible under certain
conditions)
Quinine + cycline
France Atovaquone-proguanil
Artemether-lumefantrine
R : Ambulatory treatment
possible on the basis of
specific clinical and
biological parameters
Germany Atovaquone-proguanil
Artemether-lumefantrine
R : hospitalization
recommended until
treatment completed
and patient
parasite-free
Mefloquine
Italy Atovaquone-proguanil SP : hospitalization
(ambulatory treatment
possible under
certain conditions)
Mefloquine
Spain Quinine + cycline or
clindamycin
Atovaquone-proguanil
SP: hospitalization
(ambulatory treatment
possible under
certain conditions)
Switzerland Artemether-lumefantrine
Atovaquone-proguanil
SP: hospitalization
(ambulatory treatment
possible under
certain conditions)
United Kingdom Atovaquone-proguanil R : Systematically, at least
24 h
Artemether-lumefantrine
Quinine + cyclines
The Netherlands Atovaquone-proguanil
Artemether-lumefantrine
SP: hospitalization
(ambulatory treatment
possible under
certain conditions)
Quinine + cyclines
Chloroquine*
*selected areas with known chloroquine-sensitive P. falciparum, e.g. Central
America.
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occurs usually between day 14 and day 30 after treat-
ment, physicians should organize a “recapture” system
for these patients, even limited to a call, in order to
identify promptly a possible recrudescence [15,19,36].Under treatment, mean PCT and FCT were 72 and
48 hours, respectively, which is consistent with the lit-
erature even if direct comparisons are not easy, since
methodology to calculate PCT and FCT may differ
between studies [15-20,22,25]. Nevertheless, it appeared
that, compared to other regimens including artemether-
lumefantrine, both PCT and FCT were shorter in
patients treated with artemether-mefloquine, which is
not a common regimen for imported malaria (or in
endemic areas as well) [13,37,38]. Apart from the bias
due to the study design, the difference between both
regimens containing artemether can be explained by a
higher dosage at day 0 of artemether in the artemether-
mefloquine combination compared to artemether-
lumefantrine (300 mg and 180 mg, respectively). On the
opposite, and not surprisingly so, in view of this combin-
ation being slow-acting, PCT and FCT were reported
as being longer for atovaquone-proguanil as for other
regimens [5,9,15-18]. This is possibly the reason for
the reported progression towards severity observed in
two atovaquone-proguanil patients, leading to a second-
line treatment.
Adverse events were overall relatively frequent (16%),
with quinine exhibiting the least favourable tolerance
profile. Although none of the adverse events was classi-
fied as severe, they constituted the main cause for
switching over to second-line treatment in 10% of
patients. Vomiting, mainly due to atovaquone-proguanil
but also mefloquine, was the leading cause of change
and led frequently to an intravenous treatment (quinine).
In the present study, atovaquone-proguanil was by far
the most frequent regimen prescribed, providing the op-
portunity to describe a large cohort of malaria patients
treated by this drug in “real-life” conditions. Even if the
cure rate was good and statistically comparable to the
other regimens, three relapses and two cases of progres-
sion to severe malaria were observed, possibly due to
poor absorption. In addition, PCT was longer compared
to the other regimens. The rate of adverse events was
13%, better than that one of quinine but vomiting
appeared to be specifically related to that regimen lead-
ing in a high proportion to a second-line treatment.
Surprisingly, these digestive side-effects were not clearly
reported in studies both performed in endemic areas or
in non-endemic areas and were only suggested in one
study on imported malaria [5,9,15,17,18,32,39,40].
Whilst this study constitutes the largest cohort
reported on falciparum malaria imported to Europe
to date, it has numerous limitations mainly due to its
observational design and its overall limited number of
observations; and the patient collective being heteroge-
neous with “centre effects”. For example, it was impos-
sible to standardize timing of follow-up testing for
fever and parasite clearance. Consequently, comparisons
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significant, have to be carefully interpreted. Nevertheless,
the methodology used here is the only way to observe a
large cohort of imported-malaria patients in routine
conditions as data in this specific field of malaria are
very limited. To that end, the collection of observational
data on the scale of what is presented here should be
perpetuated and extended to additional sites involved in
the treatment of malaria imported into Europe.Conclusions
Despite limitations in its design, this observational mul-
ticentre European study of 504 patients with uncompli-
cated falciparum malaria offers relevant data on
management of imported malaria in Europe. The
hospitalization rate appeared high with heterogeneity be-
tween centres. The number of treatment regimens was
as high as eighteen. Atovaquone-proguanil, the most
prescribed drug in this study, appeared to be a valuable
option but poor absorption, delay in PCT and FCT and
vomiting, frequently inducing a second-line treatment
are limiting factors. Due to a poor tolerance profile pos-
sibly leading to prolongation of hospitalization, quinine
alone should not be recommended any more as a first-
line treatment. The study results, by highlighting the
current diversity of actual treatments against a backdrop
of national and supranational guidelines which favour
few established regimens, should stimulate and an inten-
sified consensus discussion at European level, which is
desirable in order to more strictly select a limited num-
ber of treatments and to foster standardized manage-
ment of imported malaria.Additional file
Additional file 1: Main characteristics of 504 malaria patients in
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